Navigation Links
ISTA Pharmaceuticals Receives Action Date for FDA Review of Once-Daily XiDay(TM)
Date:3/8/2010

IRVINE, Calif., March 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).  The FDA has granted XiDay a standard review time of ten months, assigning ISTA a Prescription Drug User Fee Act (PDUFA) action date of October 16, 2010.  ISTA's request for a shorter, six-month priority review is still under consideration by the FDA.

Xibrom™ (bromfenac ophthalmic solution)

ISTA currently markets Xibrom (bromfenac ophth
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... LAGUNA HILLS, Calif. , July 30, 2015 ... developing nanoparticle drug delivery platforms, has received Orphan ... (FDA) for a second drug product that uses ... is a formulation of dactinomycin for the treatment ... bone cancer. The FDA granted NanoSmart,s Orphan Drug ...
(Date:7/30/2015)... , July 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ... conference call and webcast at 5:00 p.m. Eastern Time ... to discuss second quarter 2015 financial results and provide ... after the NASDAQ Global Select Market closes that day. ... dialing 877.643.7155 for domestic callers and 914.495.8552 for international ...
(Date:7/30/2015)... , July 30, 2015 EnteroMedics Inc. ... using neuroblocking technology to treat obesity, metabolic diseases and ... a conference call on Thursday, August 6, 2015, at ... the second quarter ended June 30, 2015, and to ... vBloc® Neurometabolic Therapy, delivered via the Maestro® System. ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3
... July 28 Accuray Incorporated (Nasdaq: ARAY ), a global leader in ... quarter and fiscal year 2010, ended June 30, 2010 on Tuesday, ... , , ... / 5:00 p.m. ET and will be hosted by Euan S. Thomson ...
... , July 28 HemaQuest Pharmaceuticals, a ... sickle cell disease, beta thalassemia and EBV-related cancers, announced ... to its Series B financing by new investor, Latterell ... financing to $16M . The financing is intended ...
Cached Medicine Technology:Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 2Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 3Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 4HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2
(Date:7/31/2015)... ... July 31, 2015 , ... David Gilpin, ... website to inform potential Nashville area sinus sufferers about the benefits ... to determine if someone is a good candidate for Balloon Sinuplasty. The questionnaire ...
(Date:7/30/2015)... Tucson, AZ (PRWEB) , ... July 31, 2015 , ... ... getaways may seem impossible or out-of-reach. The questions race through your mind: What happens ... is a storm? You feel overwhelmed and cancel your plans. , But not taking ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human ... More, **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – ... of helping drug, biologic and device firms reduce manufacturing errors by 50 percent ...
(Date:7/30/2015)... ... July 31, 2015 , ... On July 22nd the ... Manatee county to discuss plausible solutions for controlling the heroin outbreak. Ultimately the committee ... an overdose is largely perpetuating the heroin crisis in North Florida. The task force ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, a vertically ... invention that can help people during emergencies. , "The worldwide mobile health market ... Director of World Patent Marketing. "Currently, there are about 97,000 mobile health apps ...
Breaking Medicine News(10 mins):Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5
... Barcelona, Spain: An experimental drug that attacks cancer in ... advanced melanoma, delaying progression of the disease and prolonging ... (Wednesday) at the European Cancer Conference (ECCO 14) in ... to chemotherapy more than doubled the amount of time ...
... 26 Biomedtex Inc.,(Pink Sheets: PDNL.PK) ("Biomed" or ... that A. Marc Rocca, 42, will be,President and ... mission is to identify, evaluate and assess a ... and then,seek to capture and promote innovations with ...
... Nycomed Acquires Exclusive Rights Outside North America in Deal Valued ... ... N.J. and ZURICH, Switzerland, Sept. 26, NPS Pharmaceuticals, Inc. (Nasdaq: ... into a definitive agreement,which licenses to Nycomed the rights to ...
... research has yielded a clearer picture of which biomarkers ... colon cancer, bringing closer the day when patients who ... those that will, get the more aggressive treatment they ... doctors plan treatment of colon cancer chiefly by staging ...
... work investigating the reproducibility of glycemic index values, ... Research Center on Aging at Tufts University (USDA ... determinations (measure of the rate of glucose absorption ... white bread, resulted in a relatively high level ...
... to Home and the ... ... pioneer and largest provider of retail-,based health care in the United ... stores in Southeastern,Pennsylvania and Southern New Jersey. MinuteClinic plans to open ...
Cached Medicine News:Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2Health News:Glycemic index values are variable, report researchers 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 3Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 4Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 5
Includes one aluminum pediatric eye shield and one eye garter shield cover. Packaged 50 per box. White only....
Non-linting, quick absorption and rounded corners. Tapered malleable handle. Dispenser carton contains 25 envelopes, each envelope contains 10 sponges packaged sterile in Tyvek peel-back pouch....
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Medicine Products: